BMIP, launched by government, will function complimentary to international insurers as its global recognition requires time ...

Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...

Jose Paul is a veteran port administrator with over three decades of experience in India’s maritime sector. Born in Njarackal in Ernakulam district, he began hi ...

AMD EPYC is poised for the AI CPU supercycle, powering inference and agentic AI with strong TCO and efficiency—alongside Instinct & Helios. Click for this update.

The Acting Chief Executive Officer of the proposed National Institute for Public Health and Infectious Diseases, Zaria, ...

Anyone looking to upgrade their breakfast setup may be interested in Dunelm's "work of art" retro-style gloss toaster ...

Creative Biolabs has expanded its complement testing capabilities to help researchers overcome challenges in complement drug development through comprehensive complement activity assays, CH50 ...

ARVO presenters conducted a retrospective study to assess the visual and anatomical outcomes of patients receiving complement inhibitors for geographic atrophy. In a real-world cohort of patients with ...

(Getty) Recent developments in complement biology and targeted therapies represent important advancements in addressing some of the unresolved challenges in AAV. Despite major therapeutic advances, ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...